Wnt/β-Catenin Pathway-Mediated <em>PD-L1</em> Overexpression Facilitates the Resistance of Non-Small Cell Lung Cancer Cells to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
pubmed: wnt1 2024-12-21
Summary:
CONCLUSION: Activation of the Wnt/β-catenin pathway mediates the high expression of PD-L1 to promote the resistance of NSCLC cells to icotinib. Thus, targeted inhibition of PD-L1 expression is of benefit for the treatment of NSCLC.